SHR-3821 for Advanced Colorectal Cancer That Didn't Respond to Prior Treatment
Part of Cancer, Digestive system clinical trials.
This study tests a new drug called SHR-3821 in patients with colorectal cancer that has spread or come back after at least two rounds of standard chemotherapy. The goal is to see if this drug can slow or shrink the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your colorectal cancer must be confirmed by biopsy or cell sample and cannot be surgically removed
- You must have received at least two prior lines of chemotherapy that included oxaliplatin, irinotecan, and fluoropyrimidine drugs
- You must be between 18 and 75 years old
- Your overall health must be good enough for treatment (ECOG score 0–1: able to do normal activities or mostly able to)
- You must have at least one measurable tumor on imaging scans
- Your blood counts, liver, kidney, and heart function must meet specific healthy ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three drugs for people with advanced colorectal cancer that has not responded to previous treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
This trial tests a combination of two oral chemotherapy drugs, fruquintinib and S-1, for people with metastatic colorectal cancer that has worsened after standard treatments. The goal is to see if this new combination can help shrink or control the cancer.
This trial tests a new combination of three treatments (a drug called QL1706, a targeted therapy called fruquintinib, and a short course of radiation) for people with colorectal cancer that has spread to the liver and has normal DNA repair. The goal is to see if this combination works better than the usual third-line therapy.
This study tests a new drug called SHR-A1904 for people with advanced colorectal cancer that has not responded to at least two prior treatments. It aims to see if this drug can help shrink or control the cancer.
This trial tests a new drug called SHR-3821 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.